Recognition of melanoma-derived antigens by CTL: Possible mechanisms involved in down-regulating anti-tumor T-cell reactivity

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 55-63

  Rivoltini, Licia ^a   Loftus, Douglas J ^b   Squarcina, Paola ^a   Castelli, Chiara ^a   Rini, Francesca ^a   Arienti, Flavio ^a   Belli, Filiberto ^a   Marincola, Francesco M ^b   Geisler, Cartsen ^c   Borsatti, Alessandro ^d   Appella, Ettore ^b   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Antagonism; Immunotherapy; Peptides

Indexed keywords

CANCER VACCINE; DIFFERENTIATION ANTIGEN; MELANOMA ANTIGEN; EPITOPE; HLA A1 ANTIGEN; HLA A2 ANTIGEN; MAGEA3 PROTEIN, HUMAN; MART 1 MELAN A(27 35) EPITOPE; MART-1-MELAN-A(27-35) EPITOPE; MART1 ANTIGEN; PEPTIDE; TUMOR ANTIGEN; TUMOR PROTEIN; VIRUS ANTIGEN;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; IMMUNIZATION; IMMUNOREGULATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; ARTICLE; IMMUNOLOGY; T LYMPHOCYTE; VACCINATION;

ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CANCER VACCINES; DOWN-REGULATION; EPITOPES; EPITOPES, T-LYMPHOCYTE; HLA-A1 ANTIGEN; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; MELANOMA; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0030713422     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Maio, M. and Parmiani, G., Melanoma immunotherapy: new dreams or solid hopes? Immunol. Today, 17, 405-407, 1996.
2. Rosenberg, S. A., Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens, J. Natl. Cancer Inst., 88, 1635-1644, 1996.
3. Boon, T. and van der Bruggen, P., Human tumor antigens recognized by T lymphocytes, J. Exp. Med., 183, 725-729, 1996.
4. Kawakami, Y., Robbins, P. F., Wang, R. F., and Rosenberg, S. A., Identification of tumor-regression antigens in melanoma, Important Adv. Oncol., 3-21, 1996.
5. Van den Eynde, Peeters, O., De Backer, O., Gaugler, B., Lucas, S., and Boon, T., A new family of genes coding for an antigen recognized by autologous CTL on human melanoma, J. Exp. Med., 182, 689-698, 1995.
6. Cells, E., Tsai, V., and Crimi, C., Induction of antitumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes, Proc. Natl. Acad. Sci. U.S.A., 91, 2105-2110, 1995.
7. Salgaller, M. L., Weber, J. S., Boenig, S., Yannelli, J. R., and Rosenberg, S. A., Generation of specific anti-melanoma reactivity by stimulation of tumorinfiltrating lymphocytes with MAGE-1 synthetic peptide, Cancer Immunol. Immunother., 39, 105-112, 1994.
8. Spagnoli, G. C., Schaefer, C., Willimann, T. E., Kocher, T., Amoroso, A., Juretic, A., Zuber, M., Luscher, U., Harder, F., and Heberer, M., Peptidespecific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1 positive patients, Int. J. Cancer, 64, 309-315, 1995.
9. Jaeger, E., Bernhard, H., Romero, P., Ringhoffer, M., Arand, M., Karbaeh, J., Ilsemann, C., Hagedorn, M., and Knuth, A., Generation of CTL responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens, Int. J. Cancer, 66, 162-169, 1996.
10. van Elsas, A., van der Burg, S.-H., van der Minne, C. E., Borghi, M., Mourer, J. S., Melief, C. J. M., and Schrier, P. I., Peptide-pulsed cells induce tumoricidal CTL from healthy donors against stably HLA-A*0201 -binding peptides from Melan A/ MART-1 self antigen, Eur. J. Immunol., 26, 1683-1689, 1996.
11. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of the HLA-A2 restricted tumor infiltrating lymphocytes, J. Exp. Med., 180, 347-352, 1994.
12. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., and Rosenberg, S. A., Induction of tumor-reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro sensitization with an immunodominant peptide of the human melanoma antigen MART/1, J. Immunol., 154, 2257-2265, 1995.
13. Marincola, F. M., Rivoltini, L., Salgaller, M. L., Player, M., and Rosenberg, S. A., Differential anti/ MART1/Melan A activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells, J. Immunother., 19, 266-277, 1996.
14. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y., Canon, J-L., Laurent, C., Naeyaert, J-M., Plagne, R., Deraemaeker, R., Knuth, A., Jager, E., Brasseur, F., Herman, J., Coulie, P. G., and Boon, T., Tumor regression in melanoma patients treated with a peptide encoded by gene MAGE-3, Int. J. Cancer, 63, 883-885, 1995.
15. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A, Cancer J. Sci. Am., 3, 37-44, 1996.
16. Loftus, D. J., Castelli, C., Clay, T. M., Squarcina, P., Marincola, F. M., Nishimura, M. L, Parmiani, G., Appella, E., and Rivoltini, L., Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35), 7. Exp. Med., 184, 647-657, 1996.
17. Jameson, S. C. and Bevan, M. J., T cell receptor antagonists and partial agonists, Immunity, 2, 1-11, 1995.
18. Davenport, M. P., Antagonists or altruists: do viral mutants modulate T-cell responses? Immunol. Today, 16, 432-436, 1995.
19. Kersh, G. J. and Alien, P. M., Essential flexibility in the T-cell recognition of antigen, Nature, 380, 495-498, 1996.
20. Kiessiing, R., Kono, K., Petersson, M., and Wasserman, K., Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules, Springer Sem. Immunopathol., 18, 227-242, 1996.
21. Hanhe, M., Rimoldi, D., Schroter, M., Romero, P., Schrier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J., Melanoma cell expression of Fas(Apo1/CD95) ligand: implications for tumor escape, Science, 274, 1363-1366, 1996.
22. Ferrone, S. and Marincola, F. M., Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, Immunol. Today, 16, 487-494, 1995.
23. Rivoltini, L., Barracchini, K. C., Viggiano, V., Kawakami, Y., Smith, A., Mixon, A., Restifo, N. P., Topalian, S. L., Simonis, T. B., Rosenberg, S. A., and Marincola, F. M., Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes, Cancer Res., 55, 3149-3157, 1995.
24. Townsend, S. E. and Allison, J. P., Tumor rejection after direct costimulation of CDS T cells by B7-transfected melanoma cells, Science, 259, 369-372, 1993.